Click on a filter below to refine your search. Remove a filter to broaden your search.
Did you mean: harper/m
At the prespecified 104-week time point, semaglutide was associated with a lesser decline in eGFR than placebo.
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.
Individuals with frontotemporal lobar degeneration were accurately differentiated from controls with smartphone tests.